Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.

Ghosn M, Saroufim A, Kattan J, Chahine G, Nasr F, Farhat F.

Med Oncol. 2012 Dec;29(4):2831-7. doi: 10.1007/s12032-012-0197-9.

PMID:
22392197
2.

FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.

Ghosn M, Farhat F, Kattan J, Younes F, Moukadem W, Nasr F, Chahine G.

Am J Clin Oncol. 2007 Feb;30(1):15-20.

PMID:
17278889
3.

Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

Cancer Invest. 2003;21(4):489-96.

PMID:
14533437
4.

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.

Invest New Drugs. 2005 Aug;23(4):369-75. Erratum in: Invest New Drugs. 2005 Dec;23(6):603. Kopteridis, Petros [corrected to Kopterides, Petros].

PMID:
16012797
5.

The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.

Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R.

Tumori. 2000 Nov-Dec;86(6):465-9.

PMID:
11218187
6.

Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.

Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e749-57. doi: 10.1016/j.ijrobp.2010.10.034.

PMID:
21420250
7.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR.; GISCAD..

J Clin Oncol. 2005 May 20;23(15):3509-16.

PMID:
15908661
8.

[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].

Yan D, Dai H.

Zhonghua Zhong Liu Za Zhi. 2009 Mar;31(3):217-9. Chinese.

PMID:
19615264
9.

Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.

Li J, Merl M, Lee MX, Kaley K, Saif MW.

Expert Opin Drug Saf. 2010 Mar;9(2):207-13. doi: 10.1517/14740330903555181.

PMID:
20095915
10.

Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.

Ch'ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J, Chen LT.

J Gastroenterol Hepatol. 2006 May;21(5):874-9.

PMID:
16704539
11.

Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.

Hwang IG, Jang JS, Oh SY, Rho MH, Lee S, Park YS, Park JO, Nam EM, Lee HR, Jun HJ, Chi KC.

Cancer Chemother Pharmacol. 2015 Apr;75(4):757-62. doi: 10.1007/s00280-015-2691-1.

PMID:
25677446
12.

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study.

Zaanan A, Trouilloud I, Markoutsaki T, Gauthier M, Dupont-Gossart AC, Lecomte T, Aparicio T, Artru P, Thirot-Bidault A, Joubert F, Fanica D, Taieb J.

BMC Cancer. 2014 Jun 14;14:441. doi: 10.1186/1471-2407-14-441.

13.

Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.

El-Hadaad HA, Wahba HA.

J Gastrointest Cancer. 2013 Sep;44(3):313-7. doi: 10.1007/s12029-013-9495-5.

PMID:
23606201
14.

[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].

Gong JF, Zhang XD, Li J, Di LJ, Jin ML, Shen L.

Ai Zheng. 2007 Aug;26(8):890-4. Chinese.

PMID:
17697554
15.

PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.

Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V.

Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7.

PMID:
18391598
16.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L.

J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898.

PMID:
18421053
17.

Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer.

Ch'ang HJ, Huang CL, Wang HP, Shiah HS, Chang MC, Jan CM, Chen JS, Tien YW, Hwang TL, Lin JT, Cheng AL, Whang-Peng J, Chen LT.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1173-9. doi: 10.1007/s00280-009-0980-2.

PMID:
19319535
18.

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.

Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G, Thomas K, Oates J, Chau I.

J Clin Oncol. 2009 Nov 20;27(33):5499-505. doi: 10.1200/JCO.2008.21.5384.

PMID:
19858399
19.

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.

Am J Clin Oncol. 2009 Aug;32(4):348-52. doi: 10.1097/COC.0b013e31818c08ff.

PMID:
19363436
20.

Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.

Murad AM, Guimarães RC, Aragão BC, Rodrigues VH, Scalabrini-Neto AO, Padua CA, Moore FC.

Am J Clin Oncol. 2003 Apr;26(2):151-4.

PMID:
12714886
Items per page

Supplemental Content

Support Center